Serum 25-hydroxy vitamin-D levels in head and neck cancer chemoradiation therapy: Potential in cancer therapeutics.

IF 0.9 4区医学 Q4 ONCOLOGY

Indian journal of cancer Pub Date : 2024-04-01 Epub Date: 2024-09-11 DOI:10.4103/ijc.IJC_358_20

Arya Bhanu, Chaitali M Waghmare, Vandana S Jain, Hemant J Pawar

{"title":"Serum 25-hydroxy vitamin-D levels in head and neck cancer chemoradiation therapy: Potential in cancer therapeutics.","authors":"Arya Bhanu, Chaitali M Waghmare, Vandana S Jain, Hemant J Pawar","doi":"10.4103/ijc.IJC_358_20","DOIUrl":null,"url":null,"abstract":"Background: To evaluate the relation between serum-25-hydroxy Vitamin-D levels (S25OHVDL) and concurrent chemoradiation therapy (CTRT) toxicities in patients of head and neck squamous cell cancer (HNSCC).Methods: After an institutional ethics committee approval, consecutive HNSCC patients who received radical/adjuvant CTRT were prospectively evaluated. Patients were assessed for CTRT toxicities using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE-v5.0) and the response was evaluated according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST-1.1). S25OHVDL was assessed at the time of the first follow-up. Patients were divided into group A (Optimal) and group B (suboptimal) according to S25OHVDL. The treatment toxicities were correlated with S25OHVDL.Results: Twenty-eight patients were evaluated for the study. S25OHVDL was optimal in eight (28.57%) and suboptimal in 20 patients (71.42%). Mucositis and radiation dermatitis were significantly more in subgroup B ( P -value 0.0011 and 0.0505, respectively). Relatively lower but nonsignificant hemoglobin and peripheral white blood cell counts were observed in subgroup B.Conclusion: Suboptimal S25OHVDL was associated with significantly more skin and mucosal toxicities in HNSCC patients treated with CTRT.","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"403-407"},"PeriodicalIF":0.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijc.IJC_358_20","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To evaluate the relation between serum-25-hydroxy Vitamin-D levels (S25OHVDL) and concurrent chemoradiation therapy (CTRT) toxicities in patients of head and neck squamous cell cancer (HNSCC).

Methods: After an institutional ethics committee approval, consecutive HNSCC patients who received radical/adjuvant CTRT were prospectively evaluated. Patients were assessed for CTRT toxicities using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE-v5.0) and the response was evaluated according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST-1.1). S25OHVDL was assessed at the time of the first follow-up. Patients were divided into group A (Optimal) and group B (suboptimal) according to S25OHVDL. The treatment toxicities were correlated with S25OHVDL.

Results: Twenty-eight patients were evaluated for the study. S25OHVDL was optimal in eight (28.57%) and suboptimal in 20 patients (71.42%). Mucositis and radiation dermatitis were significantly more in subgroup B ( P -value 0.0011 and 0.0505, respectively). Relatively lower but nonsignificant hemoglobin and peripheral white blood cell counts were observed in subgroup B.

Conclusion: Suboptimal S25OHVDL was associated with significantly more skin and mucosal toxicities in HNSCC patients treated with CTRT.

查看原文本刊更多论文

头颈癌化学放疗中的血清 25- 羟基维生素-D 水平：癌症治疗的潜力

研究背景评估头颈部鳞状细胞癌（HNSCC）患者血清-25-羟基维生素-D水平（S25OHVDL）与同期化放疗（CTRT）毒性之间的关系：经机构伦理委员会批准后，对接受根治性/辅助性 CTRT 的连续 HNSCC 患者进行了前瞻性评估。采用不良事件通用术语标准 5.0 版（CTCAE-v5.0）评估患者的 CTRT 毒性，并根据实体瘤反应评估标准 1.1 版（RECIST-1.1）评估反应。S25OHVDL在首次随访时进行评估。根据 S25OHVDL 将患者分为 A 组（最佳）和 B 组（次佳）。治疗毒性与S25OHVDL相关：研究评估了 28 名患者。8名患者（28.57%）的S25OHVDL为最佳，20名患者（71.42%）的S25OHVDL为次佳。粘膜炎和放射性皮炎在 B 亚组中明显增多（P 值分别为 0.0011 和 0.0505）。B 亚组的血红蛋白和外周血白细胞计数相对较低，但无明显变化：结论：S25OHVDL不达标与接受CTRT治疗的HNSCC患者皮肤和粘膜毒性明显增加有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian journal of cancer Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Indian Journal of Cancer (ISSN 0019-509X), the show window of the progress of ontological sciences in India, was established in 1963. Indian Journal of Cancer is the first and only periodical serving the needs of all the specialties of oncology in India.